erlotinib

Combination therapy shows promise for hereditary papillary kidney cancer

By Sharon Deveson Kell|2025-06-20T15:30:06+00:0020 Jun 2025|Drug treatments|

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated papillary RCC is [...]

Comments Off

ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

By Sharon Kell|2020-06-02T14:18:52+00:002 Jun 2020|Uncategorized|

Results from a phase II study of bevacizumab and erlotinib [...]

Comments Off

Bevacizumab plus erlotinib combination for advanced HLRCC

By Sharon Kell|2019-04-01T08:42:00+00:001 Apr 2019|Drug treatments|

A recent study, published in Cancer Research and Treatment in [...]

Comments Off

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

By Sharon Kell|2017-04-10T11:46:46+00:0010 Apr 2017|Drug treatments, Subtypes of RCC|

In this video, Dr W. Marston Linehan, chief of the [...]

Comments Off

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org